BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today ...

Citi analyst Samantha Semenkow initiated coverage of BioAge Labs (BIOA) with a Buy rating and $45 price target BioAge is a clinical-staged ...

The interest in the obesity treatment landscape among pharmaceutical companies also leads Citi to consider BioAge Labs as a possible target for mergers and acquisitions, should the drug's proof-of ...

Oct. 30, 2024 — Young people with severe obesity who underwent weight-loss surgery at age 19 or younger continued to see sustained weight loss and resolution of common obesity-related ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

As of the last twelve months ending Q2 2024, BioAge's market capitalization stands at $854.6 million, reflecting investor interest in its innovative approach to treating obesity. Despite the positive ...

Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today announced ...